Clinical Validation

(Stewardson et al., Thyroid, 2023)

ThyroSPEC underwent clinical validation on 64 AUS/FLUS and 33 FN/SFN consecutive CytoLyt FNAC with histologic diagnoses, data presented at the 2019 American Thyroid Association Annual Meeting (Stewardson et al., ATA, 2019).

For 26% pre-test risk of malignancy in the AUS/FLUS category:

Sensitivity:55%
Specificity:88%
Positive Predictive Value (PPV):61%
Negative Predictive Value (NPV):85%

For 43% pre-test risk of malignancy in the FN/SFN category:

Sensitivity:38%
Specificity:75%
Positive Predictive Value (PPV):54%
Negative Predictive Value (NPV):62%